Impact of Replacing Smear Microscopy with Xpert MTB/RIF for Diagnosing Tuberculosis in Brazil: A Stepped-Wedge Cluster-Randomized Trial
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Abundant evidence on Xpert MTB/RIF accuracy for diagnosing tuberculosis (TB) and rifampicin resistance has been produced, yet there are few data on the population benefit of its programmatic use. We assessed whether the implementation of Xpert MTB/RIF in routine conditions would (1) increase the notification rate of laboratory-confirmed pulmonary TB to the national notification system and (2) reduce the time to TB treatment initiation (primary endpoints). METHODS AND FINDINGS: We conducted a stepped-wedge cluster-randomized trial from 4 February to 4 October 2012 in 14 primary care laboratories in two Brazilian cities. Diagnostic specimens were included for 11,705 baseline (smear microscopy) and 12,522 intervention (Xpert MTB/RIF) patients presumed to have TB. Single-sputum-sample Xpert MTB/RIF replaced two-sputum-sample smear microscopy for routine diagnosis of pulmonary TB. In total, 1,137 (9.7%) tests in the baseline arm and 1,777 (14.2%) in the intervention arm were positive (p<0.001), resulting in an increased bacteriologically confirmed notification rate of 59% (95% CI = 31%, 88%). However, the overall notification rate did not increase (15%, 95% CI = -6%, 37%), and we observed no change in the notification rate for those without a test result (-3%, 95% CI = -37%, 30%). Median time to treatment decreased from 11.4 d (interquartile range [IQR] = 8.5-14.5) to 8.1 d (IQR = 5.4-9.3) (p = 0.04), although not among confirmed cases (median 7.5 [IQR = 4.9-10.0] versus 7.3 [IQR = 3.4-9.0], p = 0.51). Prevalence of rifampicin resistance detected by Xpert was 3.3% (95% CI = 2.4%, 4.3%) among new patients and 7.4% (95% CI = 4.3%, 11.7%) among retreatment patients, with a 98% (95% CI = 87%, 99%) positive predictive value compared to phenotypic drug susceptibility testing. Missing data in the information systems may have biased our primary endpoints. However, sensitivity analyses assessing the effects of missing data did not affect our results. CONCLUSIONS: Replacing smear microscopy with Xpert MTB/RIF in Brazil increased confirmation of pulmonary TB. An additional benefit was the accurate detection of rifampicin resistance. However, no increase on overall notification rates was observed, possibly because of high rates of empirical TB treatment. TRIAL REGISTRATION: ClinicalTrials.gov NCT01363765. Please see later in the article for the Editors' Summary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309
Improving the reporting of pragmatic trials: An extension of the CONSORT statement
Zwarenstein, M., Treweek, S., Gagnier, J. J., Altman, D. G., Tunis, S., Haynes, B., Oxman, A. D., Moher, D., & groups, F. T. C. A. P. T. I. H. (. (2008) · BMJ · doi:10.1136/bmj.a2390 · Cited by 1,813
Grading quality of evidence and strength of recommendations for diagnostic tests and strategies
Schünemann, H. J., Oxman, A. D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G. E., Williams, J. W., Kunz, R., Craig, J., Montori, V. M., et al. (2008) · BMJ · doi:10.1136/bmj.39500.677199.ae · Cited by 1,782
The stepped wedge trial design: a systematic review
Brown, C. A., & Lilford, R. J. (2006) · BMC Medical Research Methodology · doi:10.1186/1471-2288-6-54 · Cited by 907
Studies With Staggered Starts: Multiple Baseline Designs and Group-Randomized Trials
Rhoda, D. A., Murray, D. M., Andridge, R. R., Pennell, M. L., & Hade, E. M. (2011) · American Journal of Public Health · doi:10.2105/ajph.2011.300264 · Cited by 69
Cited by
Albert, H., Nathavitharana, R. R., Isaacs, C., Pai, M., Denkinger, C. M., & Boehme, C. C. (2016) · European Respiratory Journal · doi:10.1183/13993003.00543-2016 · Cited by 300
Marley, G., Zou, X., Nie, J., Cheng, W., Xie, Y., Liao, H., Wang, Y., Tao, Y., Tucker, J. D., Sylvia, S., et al. (2023) · PLOS Medicine · doi:10.1371/journal.pmed.1004091 · Cited by 28
Naidoo, P., Dunbar, R., Lombard, C., du Toit, E., Caldwell, J., Detjen, A., Squire, S. B., Enarson, D. A., & Beyers, N. (2016) · PLOS ONE · doi:10.1371/journal.pone.0150487 · Cited by 23
Agizew, T., Chihota, V., Nyirenda, S., Tedla, Z., Auld, A. F., Mathebula, U., Mathoma, A., Boyd, R., Date, A., Pals, S. L., et al. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4697-5 · Cited by 17
“On the basis of its accuracy, shorter turnaround time, and potentially reduced loss-to-follow-up, Xpert MTB/RIF may results in earlier diagnosis and anti-TB treatment initiation to improve patient-level clinical outcomes [7, 9, 10].”
BackgroundResult
Metadata
- Authors
- Durovni, B., Saraceni, V., van den Hof, S., Trajman, A., Cordeiro-Santos, M., Cavalcante, S., Menezes, A., & Cobelens, F.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-12-09
- Volume
- 11
- Issue
- 12
- Pages
- e1001766
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2083276190
- Cited by
- 137
- References
- 5
- FWCI
- 10.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Replacing Smear Microscopy with Xpert MTB/RIF for Diagnosing Tuberculosis in Brazil: A Stepped-Wedge Cluster-Randomized Trial. https://app.cochat.ai/papers/10.1371/journal.pmed.1001766
- The paper
- Durovni, B., Saraceni, V., van den Hof, S., Trajman, A., Cordeiro-Santos, M., Cavalcante, S., Menezes, A., & Cobelens, F. (2014). Impact of Replacing Smear Microscopy with Xpert MTB/RIF for Diagnosing Tuberculosis in Brazil: A Stepped-Wedge Cluster-Randomized Trial. PLoS Medicine. https://doi.org/10.1371/journal.pmed.1001766
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.